Aislinn Vaughan, MD
Surgical Oncology · Saint Charles, MONPI 1427084227
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Endomagnetics Ltd at 57.9% of the total. Reporting peaked in 2022 at $3,665 and has fallen 93.1% since, to $252 in 2025.
Across 25 payments — averaging $273.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endomagnetics Ltd$4K
- Axogen$1K
- KCI USA, Inc.$949
- Stryker$351
- Dilon Technologies, Inc.$342
- Leica Microsystems Inc.$54
What the payments were for
- Consulting fees$80012%
- Travel & lodging$2,83742%
- Food & beverage$2,91343%
- Entertainment$2794%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endomagnetics Ltd | 7 | $3,953 |
| Axogen | 4 | $1,180 |
| KCI USA, Inc. | 2 | $949 |
| Stryker | 9 | $351 |
| Dilon Technologies, Inc. | 2 | $342 |
| Leica Microsystems Inc. | 1 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVANCE NERVE GRAFT$1,137
- AxoGuard Nerve Connector$1,137
- AxoGuard Nerve Protector$1,137
- PREVENA$800
- HemoBlast Bellows$342
- Magseed$232
- Magtrace$232
How this compares
$6,828 in reported general payments places this provider in the 70th percentile of 24 surgical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamoxifen Citrate | 55 | $837 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $80 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Saint Charles
- Peter DipascoSaint Louis$247K
- Trang NguyenSaint Louis$11K
- Rebecca AftSaint Louis$9K
- Ana Belzarena GenoveseColumbia$8K
- Julie MargenthalerSaint Louis$8K
- Charles WoodallSpringfield$7K
- Eric KimchiColumbia$5K
- Taylor BrownSaint Louis$5K
- Timothy VreelandSaint Louis$4K
- John ShookKansas City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.